Literature DB >> 1500224

K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.

B Suchy1, C Zietz, H M Rabes.   

Abstract

Material from paraffin sections of 109 human colorectal carcinomas, mostly obtained at autopsy, was analyzed for the presence of K-ras point mutations at codon 12, position 2. Mutations at this position were found in 23 cases (21.1%). Aneuploid colorectal carcinomas showed a significantly higher prevalence of K-ras point mutations than diploid tumors, suggesting an involvement of ras mutations in the development of aneuploidy. No differences in the prevalence of K-ras mutations were observed with respect to the patients' age, sex and tumor type. In metastases, the type of ras gene mutation was always identical to that of the respective primary tumor. Mutations were not found in metastases from primary tumors devoid of ras mutations. This renders a clonal selection of K-ras mutated cells from a wild-type primary tumor during the metastatic process unlikely. However, nearly twice as many ras gene mutations were seen in metastatic than in non-metastatic primary tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1500224     DOI: 10.1002/ijc.2910520107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

2.  Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.

Authors:  Maria Arcila; Christopher Lau; Khedoudja Nafa; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

Review 3.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

Review 4.  Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

Authors:  Jara M Baas; Lisanne L Krens; Henk-Jan Guchelaar; Hans Morreau; Hans Gelderblom
Journal:  Oncologist       Date:  2011-07-08

Review 5.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

6.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.

Authors:  S Gattenlöhner; B Etschmann; V Kunzmann; A Thalheimer; M Hack; G Kleber; H Einsele; C Germer; H-K Müller-Hermelink
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

7.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors:  Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

8.  KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.

Authors:  D Soulières; W Greer; Anthony M Magliocco; D Huntsman; S Young; M-S Tsao; S Kamel-Reid
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

9.  Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy.

Authors:  W Giaretti; R Monaco; N Pujic; A Rapallo; S Nigro; E Geido
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.

Authors:  M Morrin; M Kelly; N Barrett; P Delaney
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.